AI large model-driven drug discovery CRO services

📌 Background

In 2026, demand for AI-assisted drug R&D surged. CROs integrated large models with wet-lab closed loops, shortening target discovery and molecular design cycles. Insilico Medicine's total revenue in the first half of 2026 was USD 106.3 million, up 287.2% year-over-year (company financial report data, not independently audited); XtalPi Holdings' revenue grew 73.8% year-over-year in the same period (based on its Hong Kong stock exchange results announcement). Both AI pharmaceutical companies have crossed the USD 100 million revenue threshold. Payers remain global pharmaceutical companies' R&D outsourcing budgets, and the industry has entered a commercialization boom.

👤 Target Customers

Global pharmaceutical companies and biotechnology companies that pay for outsourced drug R&D services, including target discovery, molecular design, preclinical research, and more.

💰 Revenue Streams

1) Project milestones: charge upfront payments according to R&D milestones and retain a share of R&D results; 2) AI platform subscription: charge annual platform usage subscription fees; 3) Technology licensing and co-development: charge licensing fees and upfront payments for collaborative development; 4) Preclinical research services: charge bundled service fees per project; this is an opportunity item, and no public data on scale and unit price is available yet.

🧮 Cost Structure

R&D personnel compensation, computing power and experimental facilities, biological data acquisition and cleaning, model training and maintenance, compliance and regulatory costs.

🛡️ Moat

A closed loop between large-scale biological data and wet-lab validation, continuous iteration of AI models, and accumulation of industry know-how, creating dual barriers in data and algorithms.

🔑 Keys to Success

• High-quality wet-lab data closed loop
• AI model prediction accuracy
• Deeply tied to leading pharmaceutical clients

⚠️ Risks

• Risk of new drug R&D failure
• Biological data compliance risk
• Risk of AI technology substitution eroding the value of traditional CROs

🏢 Cases

• GenScript Biotech
• Insilico Medicine
• XtalPi

📊 SWOT Analysis